None listed
Conditions
Interventions
None listed
Sponsors
Yonsei University Health System, Severance Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Those who have has been judged as radiological and histologic kidney cancer Those who have has been judged as suspicious for radiological and histologic kidney cancer Those who have read and signed the Clinical Study Agreement and the Study Agreement
Exclusion criteria
Exclusion criteria: Patients whom the researcher deemed inappropriate for this clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expression of NNMT, LCP1, and NM23A in the kidney cancer markers | — |
Secondary
| Measure | Time frame |
|---|---|
| Only expression of NNMT, a marker of renal cancer | — |
Countries
Korea, Republic of
Contacts
Public ContactSUKI KANG
Yonsei University Health System, Severance Hospital
Outcome results
None listed